CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the double ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results